The tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is metabolically converted to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in a reaction which is both stereoselective and reversible. NNAL is also a lung carcinogen, with both (R)-NNAL and (S)-NNAL inducing a high incidence of lung tumours in rats. Both NNAL and NNK undergo metabolic activation to intermediates which react with DNA to form pyridylhydroxybutyl and pyridyloxobutyl DNA adducts, respectively. DNA adduct formation by NNAL and NNK is an important step in their mechanisms of carcinogenesis. In this study, we quantified both pyridylhydroxybutyl and pyridyloxobutyl DNA phosphate adducts in the lung of rats treated with 5 ppm of (R)-NNAL or (S)-NNAL in drinking water for 10, 30, 50 and 70 weeks. In (R)-NNAL-treated rats, the pyridylhydroxybutyl and pyridyloxobutyl phosphate adducts were 4530-6920 fmol/mg DNA and 46-175 fmol/mg DNA, accounting for 45-51% and 0.3-1% of the total measured DNA phosphate and base adducts, respectively. In (S)-NNAL-treated rats, the two types of phosphate adducts were 3480-4180 fmol/mg DNA and 1180-4650 fmol/mg DNA, accounting for 30-36% and 11-38% of the total adducts, respectively. Distinct patterns of adduct formation were observed, with higher levels of NNAL-derived pyridylhydroxybutyl phosphate adducts and lower levels of NNK-derived pyridyloxobutyl phosphate adducts in the (R)-NNAL treatment group than the (S)-NNAL group. The persistence and increase over time of certain pyridylhydroxybutyl phosphate adducts over the course of the study suggest that these adducts could be useful biomarkers of chronic exposure to NNAL and NNK. The results of this study provide important new information regarding DNA damage by NNAL and NNK, and contribute to understanding mechanisms of tobacco-related carcinogenesis.
Introduction
The tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK, 1, Figure 1 ) is a potent pulmonary carcinogen in laboratory animals and, together with N′-nitrosonornicotine, is classified as a human carcinogen (Group 1) by the International Agency for Research on Cancer (1) . NNK is converted through carbonyl reduction to its metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL, 2, Figure 1 ) in various in vitro and in vivo biological systems (2, 3) . NNAL is also a potent lung carcinogen (2, 4) . Both NNK and NNAL are bioactivated upon cytochrome P450-catalysed hydroxylation to form reactive intermediates, which react with DNA to form adducts, a key step in determining the carcinogenic properties of NNK and NNAL (3, 5) . Therefore, measurement of DNA adduct formation by NNK and NNAL potentially can provide important insights into mechanisms of tobacco-associated cancer.
Metabolic activation of NNK by α-hydroxylation results in the formation of reactive intermediate 3. The intermediate 3 can decompose to 5 and then to a diazonium ion 7, which reacts with DNA to form DNA adducts. The intermediate 7 reacts with nucleobases to form pyridyloxobutyl (POB) base adducts (6) , and also reacts with the oxygen of the phosphodiester linkages in DNA to form pyridyloxobutyl phosphate adducts, or B 1 p(POB)B 2 adducts, where B 1 and B 2 represent the same or different nucleobases ( Figure 1 ) (7) . The major POB base adducts and B 1 p(POB)B 2 phosphate adducts have been characterised, and their levels have been quantified in animals treated with NNK (4, (6) (7) (8) . Like NNK, metabolic activation of NNAL by α-hydroxylation produces an intermediate 4, which similarly decomposes to a diazonium ion 8. The diazonium ion 8 reacts with DNA nucleobases to form pyridylhydroxybutyl (PHB) base adducts (8, 9) . In a separate study, we demonstrated that 8 also reacted with the oxygen of the phosphodiester linkages in DNA to form pyridylhydroxybutyl phosphate adducts B 1 p(PHB) s B 2 (Figure 1 ), where the subscript s represents 'straight chain' in DNA (10) . The intermediate 8 also rearranged to a secondary carbocation 9 (11) , which reacted with DNA to form B 1 p(PHB) b B 2 (Figure 1 ), where the subscript b represents 'branched chain' (10) . The B 1 p(PHB) s B 2 and B 1 p(PHB) b B 2 phosphate adducts are collectively named as B 1 p(PHB)B 2 phosphate adducts to indicate that both types of adducts are produced from NNAL.
NNAL has a chiral centre at the carbinol carbon and thus exists in the enantiomeric forms (R)-NNAL and (S)-NNAL. In a previous study, we reported the carcinogenicity of 5 ppm of (R)-NNAL or (S)-NNAL administered in the drinking water to male F-344 rats for up to 70 weeks. Both enantiomers selectively induced a high incidence of lung tumours (4) . The analysis of DNA adduct formation in the NNAL-treated rats could provide critical information to relate DNA damage to the carcinogenicity of these compounds. Therefore, in this study, we describe the detection and quantitation of pulmonary B 1 p(PHB)B 2 and B 1 p(POB)B 2 adducts in rats treated with (R)-NNAL or (S)-NNAL in their drinking water for 10, 30, 50 and 70 weeks. The contributions of different types of phosphate and base adducts to the total measured DNA adducts were also investigated. This study presents important new data on DNA damage caused by NNAL enantiomers, and identifies DNA phosphate adducts as potential biomarkers for mechanistic investigation of tobacco exposure-induced carcinogenesis. N 2 ]Tp(PHB) s T, were prepared as described (10) . Enzymes and reagents for DNA isolation were purchased from Qiagen Sciences (Germantown, MD, USA). All other chemicals and solvents were obtained from SigmaAldrich Chemical Co. (Milwaukee, WI, USA).
Materials and methods

Materials and chemicals
In vivo DNA samples
The in vivo DNA samples were from lung tissues of male F-344 rats (n = 3) treated chronically with 5 ppm of (R)-NNAL or (S)-NNAL in drinking water for 10, 30, 50 and 70 weeks (4). DNA was isolated using our previously developed protocol (6) , and stored at −20°C until analysis.
DNA hydrolysis and sample preparation
The DNA samples (~200 μg) were dissolved in 0.6 ml of 10 mM sodium succinate buffer (pH 7. On the next day, 20 μl of hydrolysate was collected for dGuo analysis and DNA quantitation (6) . The remaining hydrolysate was processed by filtration through 10 K centrifugal filters (Ultracel YM-10, Millipore), and purified by 30-mg Strata X cartridges (Phenomenex) activated with 2 ml of MeOH and 2 ml of H 2 O. The cartridges were washed with 2 ml of H 2 O and 1 ml of 10% MeOH sequentially and finally eluted with 2 ml of 50% MeOH. The 50% MeOH fraction containing analytes was concentrated to dryness in a centrifugal evaporator. The residue was redissolved in 10 μl of deionised H 2 O and analysed by mass spectrometry.
LC-NSI-HRMS/MS analysis
The analysis was conducted using a liquid chromatography (LC)-nanoelectrospray ionisation (NSI)-high-resolution tandem mass spectrometry (HRMS/MS) method. Briefly, the analysis was performed on an Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific, Waltham, MA, USA) using full scan, selected-ion monitoring (SIM) and product ion scan modes. For Cp(POB)C, Tp(POB)T, Cp(PHB) s C and T(PHB) s T, quantitation was based on the peak area ratio of each adduct to their corresponding isotope-labelled internal standards, the constructed calibration curves, and the amount of internal standards added. For those adducts for which standards were not available, a semi-quantitative approach was applied to estimate the levels of all the other phosphate adducts based on their MS signal intensities compared to Cp ( At the same molar amount, the MS signal intensities of Tp(POB)T and Tp(PHB) s T were five and two times higher than Cp(POB)C and Cp(PHB) s C, respectively. This observation suggests that different base combinations of the DNA phosphate adducts may have different ionisation efficiencies under the current conditions. Thus, the levels of adducts without standards were based on these semi-quantitation methods mentioned above.
All data are presented as mean ± standard deviation (SD). Comparisons of adduct levels between the (R)-NNAL and (S)-NNAL treatment groups were performed using the two-tailed unpaired t-test. Comparison of adduct levels at different time points were performed using analysis of variance (ANOVA) with Bonferroni correction for multiple comparisons. A P value less than 0.05 was considered significant.
Results
Because B 1 and B 2 represent the same or different nucleobases, there can be 10 different combinations of B 1 p(PHB)B 2 or B 1 p(POB)B 2 phosphate adducts. With B 1 and B 2 being different bases, there can be two different types of isomers: B 1 -3′-p-5′-B 2 and B 1 -5′-p-3′-B 2 . In this study, we use B 1 pB 2 to represent both types [e.g. Ap(PHB)T represents both A-3′-p(PHB)-5′-T and A-5′-p(PHB)-3′-T]. There can be 32 different isomers of B 1 p(POB)B 2 adducts due to the chiral centre in the phosphate group (Table 1) (7). Both (R)-NNAL and (S)-NNAL are re-oxidised by rat lung microsomes to NNK (12) , which is then converted back to partially racemised NNAL. Thus, there can be 64 different isomers of B 1 p(PHB) s B 2 adducts due to another chiral centre at the hydroxyl group in the structure. An additional chiral centre is introduced on the methyl-bearing carbon of B 1 p(PHB) b B 2 adducts, which can lead to formation of 128 different isomers. Therefore, there can be a total of 192 different isomers of B 1 p(PHB)B 2 adducts (Table 1) . Both B 1 p(PHB)B 2 and B 1 p(POB)B 2 adducts were analysed in the lung tissues of rats treated with (R)-NNAL and (S)-NNAL.
DNA phosphate adduct formation in (R)-NNALtreated rats
Utilising the standards of Cp(PHB) s C (Figure 2A ), the identities of Cp(PHB) s C and Cp(PHB) b C were confirmed during the analysis, and a typical chromatogram of these adducts in the lung DNA from a rat treated with (R)-NNAL for 50 weeks is presented in Figure 2B . Under the current chromatographic conditions, the two isomers of Cp(PHB) s C eluted earlier, followed by the four isomers of Cp(PHB) b C. Like Cp(PHB)C, the identities of the two types of Tp(PHB)T adducts [i.e. Tp(PHB) s T and Tp(PHB) b T] were confirmed by standards ( Figure 2C and D) . A typical chromatogram obtained upon analysis of Tp(PHB)T in the lung DNA from a rat treated with (R)-NNAL for 50 weeks is presented in Figure 2D . Tp(PHB) s T eluted earlier, followed by the four isomers of Tp(PHB) b T. The levels of Cp(PHB) s C decreased after 30 weeks, while the levels of Cp(PHB) b C increased over time, reached a peak at 50 weeks, and persisted afterwards ( Figure 3A) . Therefore, the increase and persistence of Cp(PHB) b C contributed to the overall increase of Cp(PHB)C levels over the course of the study. Similar to the isomers of Cp(PHB)C, the levels of Tp(PHB) s T decreased after 30 weeks, while the levels of Tp(PHB) b T increased over time ( Figure 3B ).
The identities of the other B 1 p(PHB)B 2 adducts without standards were based on the accurate masses of the precursor ions and the corresponding fragment ions. With Ap(PHB)T as an example, its extracted ion chromatograms upon analysis of lung DNA from a rat treated with (R)-NNAL for 50 weeks, and the proposed fragmentation pattern of Ap(PHB)C are presented in Figure 4 . Using the same strategy, at least five isomers of B 1 p(PHB)B 2 and at least one isomer of B 1 p(POB)B 2 for each set of base combinations were detected. A total of 95 out of 192 possible B 1 p(PHB)B 2 adducts and 19 out of 32 possible B 1 p(POB)B 2 adducts were chromatographically separable and detected in the lung tissue under these conditions (Table 1) . Three major B 1 p(PHB)B 2 adducts were observed, namely Cp(PHB)T, Ap(PHB)C, and Ap(PHB)T, which accounted for 18-20%, 15-16%, and 15-16% of the total B 1 p(PHB)B 2 adducts, respectively ( Figure  5A ). For most of the B 1 p(PHB)B 2 adducts, the levels increased from 10 weeks-treatment to 30 weeks-treatment, and stayed persistent throughout the rest of the study. For example, the levels of Cp(PHB) T increased from 823 ± 93 fmol/mg DNA at 10 weeks of treatment to 1290 ± 107 fmol/mg DNA at 30 weeks of treatment (P < 0.05), and were not significantly changed afterwards with levels of 1270 ± 64 and 1350 ± 91 fmol/mg DNA at 50 and 70 weeks, respectively. The B 1 p(POB)B 2 adducts were formed to a much lesser extent, ranging from 46 to 175 fmol/mg DNA over the course of the study ( Figure 5B ), compared to 4530-6920 fmol/mg DNA of B 1 p(PHB)B 2 adducts. Some base combinations, e.g. Tp(POB)T and Cp(POB)T, were not detected in the lung DNA of rats from 70 weeks of treatment ( Figure 5B ). (Table 1) . Similar to the (R)-NNAL treatment group, the three most abundant adducts were Cp(PHB)T, Ap(PHB)C, and Ap(PHB)T, which accounted for 19-23%, 11-16%, and 18-21% of the total B 1 p(PHB)B 2 adducts, respectively ( Figure 5C ). For most of the B 1 p(PHB)B 2 adducts, once formed, their levels were not significantly changed over the course of the study. Different from the B 1 p(PHB)B 2 adducts, the levels of B 1 p(POB)B 2 adducts were maximal at 10 weeks, and decreased afterwards ( Figure 5D ). For example, the level of Cp(POB)T decreased from 853 ± 93 fmol/mg DNA at 10 weeks of treatment to 232 ± 61 fmol/mg DNA at 70 weeks of treatment (P < 0.05). While the B 1 p(PHB)B 2 adduct levels between the (R)-NNAL and (S)-NNAL treatment groups were only 1.2-1.8-fold different [higher in the (R)-NNAL group, P < 0.05], the difference of B 1 p(POB)B 2 adduct levels between the two groups was more drastic, with the levels in the (S)-NNAL group 8-34 times higher than the (R)-NNAL group (P < 0.01).
DNA phosphate adduct formation in (S)-NNALtreated rats
Comparison of DNA phosphate and base adducts formed by NNAL
In addition to B 1 p(PHB)B 2 and B 1 p(POB)B 2 phosphate adducts, the levels of their corresponding base adducts (PHB and POB base adducts) were obtained from our previous studies (4), to determine the relative proportion of each type of adduct to the total identified pyridine-containing DNA adducts formed in rats treated with NNAL (Table 2) . In rat lung, the levels of two major PHB base adducts-O -[4-(3-pyridyl)-4-oxobut-1-yl]deoxyguanosine-were reported previ ously (4) . In the (R)-NNAL treatment group, B 1 p(PHB)B 2 phosphate adducts and PHB base adducts were by far the most abundant types of adducts, accounting for 45-51% and 45-50% of the total measured DNA adducts, respectively ( Figure 6A ). In the (S)-NNAL treatment group, B 1 p(POB)B 2 phosphate adducts were the most abundant type in the 10 weeks treatment group (38%), but decreased afterwards (24%, 12%, and 11% in 30, 50, and 70 weeks-treatment groups, respectively). The levels of B 1 p(PHB)B 2 phosphate adducts and POB base adducts were comparable over the course of the study, accounting for 30-36% and 26-43%, respectively, of the total measured DNA adducts, followed by PHB base adducts (7-12%) ( Figure 6B ). The total amount of measured DNA phosphate and base adducts were calculated and compared between (R)-NNAL-and (S)-NNALtreated rats ( Table 2 ). The levels of total adducts in (R)-NNAL-treated rats were lower at 10 weeks, but higher at 30 and 50 weeks than those in (S)-NNAL-treated rats (P < 0.05), while their levels were comparable at 70 weeks (Table 2) .
Discussion
In this study, we measured the formation of pyridylhydroxybutyl and pyridyloxobutyl DNA phosphate adducts in the lung of rats treated chronically with (R)-NNAL and (S)-NNAL in a carcinogenicity study. The pyridylhydroxybutyl phosphate adducts [B 1 p(PHB) B 2 ] were formed directly by metabolic activation of NNAL, while the pyridyloxobutyl phosphate adducts [B 1 p(POB)B 2 ] were formed via NNAL conversion to NNK and subsequent bioactivation of NNK (12) . Both types of phosphate adducts were detected and quantified in the two treatment groups. Like DNA base adducts in our previous studies (4, 8, 9) , distinct patterns of phosphate adduct formation were observed in the (R)-NNAL and (S)-NNAL treatment groups. The differences in DNA adduct formation are likely due to differences in metabolism of (R)-NNAL and (S)-NNAL in rats. In rat lung microsomes, the metabolism of (S)-NNAL is significantly faster than that of (R)-NNAL, notably for the formation of α-methyl hydroxylation-derived 1-(3-pyridyl)-1,4-butanediol, the product of intermediate 8 reacting with H 2 O (12). Pyridine-N-oxidation and re-oxidation to NNK are also significantly faster with (S)-NNAL as a substrate compared to (R)-NNAL (12, 13) . With different metabolic rates of the two enantiomers in rat lung, it is reasonable to expect different formation patterns of DNA adducts, and in previous studies we have observed that PHB base adducts are the major type of adduct formed from (R)-NNAL while (S)-NNAL and NNK behave similarly and produce mainly POB base adducts (9) . This trend was also observed in the present study. The levels of B 1 p(PHB)B 2 adducts (NNAL-derived) in the (R)-NNAL-treated rats were 1.2-1.8 times higher (P < 0.05) than in the (S)-NNALtreated rats. The levels of B 1 p(POB)B 2 phosphate adducts and POB base adducts (both NNK-derived) in the (S)-NNAL-treated rats were 7-34 times (P < 0.0001) and 6-10 times (P < 0.001) higher, respectively, than in the (R)-NNAL-treated rats. The different conversion rates from the two enantiomers of NNAL to NNK also resulted in different contributions of each type of adduct to the total amount of (4, 8, 9) . This finding also applies to the DNA base adduct formation by these compounds. In rat lung, the levels of total PHB base adducts were similar between (S)-NNAL and NNK groups (P > 0.05), compared to significantly higher levels in the (R)-NNAL group (P < 0.01) ( Table 2) . Similarly, the levels of total POB base adducts between the NNK and (S)-NNAL groups were only 0.5-1.4-fold [NNK/(S)-NNAL] different, compared to 4-14-fold [NNK/(R)-NNAL, P < 0.01] difference between the NNK and (R)-NNAL groups (4). At 50 and 70 weeks of treatment, the formation pattern of B 1 p(PHB)B 2 phosphate adducts in the lung tissues of rats treated with (S)-NNAL mirrored those treated with NNK (P > 0.05), while the levels were significantly higher in the (R)-NNAL group (P < 0.001, Table 2 ). However, at 10 and 30 weeks of treatment, the levels of B 1 p(PHB)B 2 phosphate adducts in NNK-treated rats were the highest, followed by the (R)-NNAL and (S)-NNAL groups. The similarity of (S)-NNAL and NNK was not observed in B 1 p(POB)B 2 phosphate adduct formation. Significantly higher (P < 0.001) levels of B 1 p(POB)B 2 adducts were formed in the (S)-NNAL group than in the NNK group. Previous studies demonstrated that (S)-NNAL is retained in the tissues of rats, specifically the lung (13, 14) , which could contribute to the formation of more B 1 p(POB)B 2 adducts in the (S)-NNAL group.
The persistence of DNA phosphate adducts in vivo has been demonstrated in previous studies. For example, methyl and ethyl DNA phosphate adducts were more persistent than their corresponding base adducts in animals treated with alkylating agents (15) (16) (17) (18) . Our studies also demonstrated that certain B 1 p(PHB)B 2 and B 1 p(POB)B 2 phosphate adducts were persistent in rats treated with NNK over the 70 weeks of treatment (7, 10) . Consistent with these previous findings, some of the phosphate adducts in the current study were also persistent over the 70 weeks of treatment in rats treated with (R)-NNAL and (S)-NNAL. Compared to the decrease over time of most base adducts, the persistence of Cp(PHB) b C and Tp(PHB) b T in the lung over time and the increase of Tp(PHB) b T in the lung of (R)-NNAL-treated rats (Figure 3 ) are particularly notable. CYP2A6 and CYP2A13, which catalyse α-hydroxylation of NNAL and NNK, were detected in human lung microsomes (19) (20) (21) , suggesting this metabolic pathway may also occur in smokers who are exposed to NNAL and NNK. Thus, the persistent DNA phosphate adducts such as Cp(PHB) b C and Tp(PHB) b T might be detected in people chronically exposed to tobacco products, suggesting their potential value as biomarkers of tobacco-associated carcinogenesis.
With such persistence in vivo, these NNAL/NNK-derived phosphate adducts may be biologically significant. Previous studies on other phosphate adducts have demonstrated the impacts of phosphate group modifications on DNA binding affinity and metabolic enzymes and helicases (22) (23) (24) (25) (26) . However, the consequences of these pyridylhydroxybutyl and pyridyloxobutyl DNA phosphate adducts are still unclear and warrant further study. With the outcomes of future studies on biological relevance of these DNA phosphate adducts, we may have a better understanding of the role of these adducts in NNALand NNK-related carcinogenesis. This study focused on measurement of pyridylhydroxybutyl and pyridyloxobutyl DNA adducts, which are specific to NNAL and NNK. Methyl-DNA base adducts were also detected in NNAL-treated rats (3, 4) , and the possible formation and characterisation of methyl-phosphate adducts in NNAL-and NNK-treated rats will be reported separately.
In summary, we quantified pyridylhydroxybutyl and pyridyloxobutyl DNA phosphate adducts formed in rats exposed to individual enantiomers of NNAL, metabolites of the tobacco-specific carcinogen NNK. Our findings demonstrate that pyridylhydroxybutyl phosphate adducts are one of the most abundant types of all identified adducts in rat lung. Some of the pyridylhydroxybutyl phosphate adducts [e.g. Tp(PHB) b T] persisted during 70 weeks of chronic treatment with individual enantiomers of NNAL. The results of this study suggest that these NNAL/NNK-derived phosphate adducts could be potential biomarkers of chronic exposure to NNAL and NNK, and could be used in future studies of tobacco carcinogenesis.
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